Cornea Sense is developing a medical diagnostic device to help eye doctors diagnose and monitor eye and metabolic diseases by providing direct and specific ocular surface hydration data.
Proudly supported by
In short
Why Now
Eye care is undergoing a major shift, and current diagnostic tools are reaching their limits.
Cornea Sense sits at the intersection of these trends:
• Rising demand for early detection of diabetes, dry eye disease, and post-surgical complications
• Hospitals and clinics seeking non-invasive, software-integrated diagnostic tools
Traction & Milestones
• Technology developed at Aalto University
• PCT patent filed + new patent disclosures in pipeline
• Functional prototype validated on phantom models
• Transitioning to first human-eye measurements
• Strong clinical advisory network (Finland, EU, US)
• Incorporated January 2026
Funding will accelerate:
• Clinical validation and regulatory pathway (MDR Class IIa)
• Device miniaturisation and production design
Investment Opportunity
We are closing our pre-seed round to:
• Complete clinical readiness and human-data validation
• Set up pilot sites across Europe and the US
We welcome early conversations with:
• Medtech and diagnostics VCs
• Strategic ophthalmology and imaging investors
• Angel syndicates focused on deeptech and healthtech
